Sumitomo Pharma America, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
SMP-3124LP in Adults With Advanced Solid Tumors
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06526819
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)
- Conditions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06517940
- Locations
- ๐บ๐ธ
Mass Eye and Ear, Boston, Massachusetts, United States
Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06389955
- Locations
- ๐บ๐ธ
Frontage Investigative Site, Secaucus, New Jersey, United States
A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06037668
- Locations
- ๐บ๐ธ
Alivation Health, LLC, Lincoln, Nebraska, United States
๐บ๐ธCNS Healthcare, Orlando, Florida, United States
๐บ๐ธCedar Clinical Research, Draper, Utah, United States
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05741528
- Locations
- ๐บ๐ธ
Advanced Research Center Inc., Anaheim, California, United States
๐บ๐ธCollaborative Neuroscience Research, LLC, Torrance, California, United States
๐บ๐ธClinical Innovations, Inc., Riverside, California, United States
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05227209
- Locations
- ๐บ๐ธ
Sun Valley Research Center, Imperial, California, United States
๐บ๐ธClinical innovations, Inc., Riverside, California, United States
๐บ๐ธAMR Conventions Research, Warrenville, Illinois, United States
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT05169710
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham Huntsville Regional Medical Campus, Huntsville, Alabama, United States
๐บ๐ธSanro Clinical Research Group LLC, Bryant, Arkansas, United States
๐บ๐ธAdvanced Research Center, Inc., Anaheim, California, United States
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05023551
- Locations
- ๐บ๐ธ
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04988555
- Locations
- ๐บ๐ธ
University of Miami, Miami, Florida, United States
๐บ๐ธSibley Memorial Hospital, Baltimore, Maryland, United States
๐บ๐ธJohns Hopkins Main Center, Baltimore, Maryland, United States
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04623996
- Locations
- ๐บ๐ธ
BRCR Global, Plantation, Florida, United States
๐บ๐ธUS Oncology - Austin Texas Oncology Midtown, Austin, Texas, United States
๐บ๐ธMontefiore Medical Center, Bronx, New York, United States